AU2022409833A1 - Nitric oxide-releasing nasal compositions and methods of use thereof - Google Patents

Nitric oxide-releasing nasal compositions and methods of use thereof Download PDF

Info

Publication number
AU2022409833A1
AU2022409833A1 AU2022409833A AU2022409833A AU2022409833A1 AU 2022409833 A1 AU2022409833 A1 AU 2022409833A1 AU 2022409833 A AU2022409833 A AU 2022409833A AU 2022409833 A AU2022409833 A AU 2022409833A AU 2022409833 A1 AU2022409833 A1 AU 2022409833A1
Authority
AU
Australia
Prior art keywords
composition
buffer
nitric oxide
optionally
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022409833A
Other languages
English (en)
Inventor
Carri Brodnax GEER
Benjamin Joseph Monroe PRIVETT
Daniel Albert RICCIO
Shaylyn Elizabeth WALTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Publication of AU2022409833A1 publication Critical patent/AU2022409833A1/en
Assigned to LIGAND PHARMACEUTICALS INCORPORATED reassignment LIGAND PHARMACEUTICALS INCORPORATED Request for Assignment Assignors: LNHC, INC.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022409833A 2021-12-17 2022-12-16 Nitric oxide-releasing nasal compositions and methods of use thereof Pending AU2022409833A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290928P 2021-12-17 2021-12-17
US63/290,928 2021-12-17
PCT/US2022/081754 WO2023114971A1 (en) 2021-12-17 2022-12-16 Nitric oxide-releasing nasal compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2022409833A1 true AU2022409833A1 (en) 2024-06-20

Family

ID=86773604

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022409833A Pending AU2022409833A1 (en) 2021-12-17 2022-12-16 Nitric oxide-releasing nasal compositions and methods of use thereof

Country Status (9)

Country Link
US (1) US20250049841A1 (https=)
EP (1) EP4447946A4 (https=)
JP (1) JP2024547022A (https=)
KR (1) KR20240125633A (https=)
CN (1) CN118742298A (https=)
AU (1) AU2022409833A1 (https=)
CA (1) CA3240044A1 (https=)
IL (1) IL313526A (https=)
WO (1) WO2023114971A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006006432D1 (de) * 2005-03-24 2009-06-04 Nolabs Ab Kosmetische behandlung mit stickoxid, vorrichtung zur durchführung dieser behandlung und herstellungsverfahren dafür
ES2731298T3 (es) * 2005-05-27 2019-11-14 Univ North Carolina Chapel Hill Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas
EP2334279A4 (en) * 2008-10-16 2013-03-20 Novan Inc STAIN OXIDE RELEASING PARTICLES FOR MOUTH CARE APPLICATIONS
WO2015138406A1 (en) * 2014-03-14 2015-09-17 12th Man Technologies, Inc. Treating diseases using nitric oxide releasing solutions
WO2016160089A1 (en) * 2015-03-27 2016-10-06 Novan, Inc. Topical antiviral compositions, delivery systems, and methods of using the same
CA2919733A1 (en) * 2014-08-08 2016-02-08 Novan, Inc. Topical compositions and methods of using the same
CN109310630A (zh) * 2016-04-13 2019-02-05 诺万公司 用于治疗感染的组合物、系统、试剂盒和方法
BR112021023632A2 (pt) * 2019-06-04 2022-04-19 Thirty Respiratory Ltd Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório
CN112791096A (zh) * 2020-12-31 2021-05-14 南京诺令生物科技有限公司 一种可自提供一氧化氮的洗鼻盐及其应用

Also Published As

Publication number Publication date
EP4447946A4 (en) 2026-01-07
CA3240044A1 (en) 2023-06-22
US20250049841A1 (en) 2025-02-13
KR20240125633A (ko) 2024-08-19
IL313526A (en) 2024-08-01
CN118742298A (zh) 2024-10-01
EP4447946A1 (en) 2024-10-23
WO2023114971A1 (en) 2023-06-22
JP2024547022A (ja) 2024-12-26

Similar Documents

Publication Publication Date Title
Brunaugh et al. Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae
JP6651499B2 (ja) 局所用抗ウイルス薬組成物及びこれを使用する方法
JP6899845B2 (ja) 感染症を治療するための組成物、システム、キットおよび方法
US20230075885A1 (en) Compositions and applications thereof
US11826382B2 (en) Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
JP7821168B2 (ja) 感染を防止するための組成物
US20220110968A1 (en) Compositions and methods to disinfect, treat and prevent microbial infections
ES2860098T3 (es) Composición para la aplicación nasal
JP2007515204A (ja) 塩化セチルピリジニウムの殺ウイルス活性
US20250049841A1 (en) Nitric oxide-releasing nasal compositions and methods of use thereof
US11642372B2 (en) Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
JP2024128022A (ja) 微生物感染を消毒、処置および予防するための組成物および方法
US12042514B2 (en) Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
CN113244262A (zh) 一种用于预防及治疗呼吸道感染性疾病的吸入粉雾制剂
WO2023021329A1 (en) Compositions and methods to disinfect, treat and prevent microbial infections
CN117083057A (zh) 用于预防感染的组合物
CN102369012B (zh) 氧化氘用于治疗病毒性呼吸道疾病的用途
US11986516B2 (en) Compositions and methods for treatment of SARS-COV-2
AU2022410715B2 (en) Pharmaceutical combination for the treatment of the respiratory infection caused by sars-cov-2
EP4380549B1 (en) Peptidase formulation for treatment of microbial infections in the upper respiratory tract
US20240091253A1 (en) THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES
CN113244263A (zh) 一种用于预防及治疗呼吸道感染性疾病的雾化吸入制剂
KR20230129017A (ko) 호흡기 병을 갖는 환자를 다루기 위한 적어도 하나의병원균에 활성인 낮은 pH 및 낮은 독성을 갖는 치료 물질

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LIGAND PHARMACEUTICALS INCORPORATED

Free format text: FORMER APPLICANT(S): LNHC, INC.